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Fluoroquinolone resistance can cause major clinical problems. Here, we investigated
fluoroquinolone resistance mechanisms in a clinical Escherichia coli isolate, HUE1, which
had no mutations quinolone resistance-determining regions (QRDRs) of DNA gyrase
and topoisomerase IV. HUE1 demonstrated MICs that exceeded the breakpoints for
ciprofloxacin, levofloxacin, and norfloxacin. HUE1 harbored oqxAB and qnrS1 on distinct
plasmids. In addition, it exhibited lower intracellular ciprofloxacin concentrations and
higher mRNA expression levels of efflux pumps and their global activators than did
reference strains. The genes encoding AcrR (local AcrAB repressor) and MarR (MarA
repressor) were disrupted by insertion of the transposon IS3-IS629 and a frameshift
mutation, respectively. A series of mutants derived from HUE1 were obtained by plasmid
curing and gene knockout using homologous recombination. Compared to the MICs of
the parent strain HUE1, the fluoroquinolone MICs of these mutants indicated that qnrS1,
oqxAB, acrAB, acrF, acrD, mdtK, mdfA, and tolC contributed to the reduced susceptibility
to fluoroquinolone in HUE1. Therefore, fluoroquinolone resistance in HUE1 is caused by
concomitant acquisition of QnrS1 and OqxAB and overexpression of AcrAB–TolC and other
chromosome-encoded efflux pumps. Thus, we have demonstrated that QRDR mutations
are not absolutely necessary for acquiring fluoroquinolone resistance in E. coli.
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INTRODUCTION
Fluoroquinolones are widely used in the clinical treatment of var-
ious bacterial infections, such as urinary tract and blood stream
infections caused by Escherichia coli. Many studies have reported
the isolation of fluoroquinolone-resistant strains (Peña et al.,
1995; Cizman et al., 2001; Sanchez et al., 2012). Fluoroquinolone
resistance is mainly caused by point mutations in the quinolone
resistance-determining regions (QRDRs) of the DNA gyrase
(encoded by gyrA and gyrB) and topoisomerase IV (encoded by
parC and parE) subunits (Yoshida et al., 1991; Conrad et al., 1996;
Heisig, 1996; Breines et al., 1997). A slight decrease in susceptibil-
ity to fluoroquinolones is attributed to a single mutation in gyrA.
Secondary mutations in gyrA and additional mutations in parC
and/or parE are required to exceed the breakpoint of the fluoro-
quinolone MIC (Conrad et al., 1996; Heisig, 1996; Breines et al.,
1997).
Recently, we reported a fluoroquinolone-resistant E. coli iso-
late without QRDR mutations, named HUE1 (Sato et al., 2011).
Its MICs for fluoroquinolones, such as ciprofloxacin (CIP) and
levofloxacin (LVX), exceeded the breakpoints established by the
Clinical and Laboratory Standards Institute (CLSI) (Clinical
and Laboratory Standards Institute, 2011). HUE1 possesses two
plasmid-mediated quinolone-resistant determinants (PMQRs),
viz., oqxAB and qnrS. In this bacterium, OqxAB is a plasmid-
encoded efflux pump; however, the gene is present on the chro-
mosomal DNA in most Klebsiella pneumoniae and Enterobacter
cloacae strains (Bin Kim et al., 2009). The presence of this
pump confers resistance to several antimicrobial agents, such as
olaquindox (OLA), trimethoprim (TMP), and chloramphenicol
(CHL), and decreases bacterial susceptibility to fluoroquinolones
(Hansen et al., 2007). QnrS, on the other hand, is a mem-
ber of the pentapeptide-repeat protein family that protects DNA
gyrase (and probably also topoisomerase IV) from binding to
fluoroquinolones, thereby decreasing fluoroquinolone suscepti-
bility (Jacoby, 2005). However, acquisition of these PMQRs alone
results in only a low level of fluoroquinolone resistance, with
MICs that do not exceed the breakpoints for fluoroquinolones
(Jacoby, 2005; Hansen et al., 2007). E. coli isolates lacking QRDR
mutations in gyrA and parC and showing concomitant acquisi-
tion of oqxAB and qnrS have previously been reported in China;
however, these isolates did not exceed the breakpoint for CIP
(Zhao et al., 2010).
Our previous findings suggested that the fluoroquinolone
resistance of HUE1, which lacks QRDR mutations, is associated
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with not only with the presence of oqxAB and qnrS but also
with other fluoroquinolone-resistance mechanism(s) (Sato et al.,
2011). In the current study, we investigated the fluoroquinolone-
resistance mechanisms of the HUE1 strain.
METHODS
BACTERIAL ISOLATES
E. coli HUE1 had been isolated from the urinary catheter of
a 77-year-old female patient at Hokkaido University Hospital
(Sapporo, Japan) in 2007 (Sato et al., 2011). The somatic (O)
serotype was determined by the slide agglutination test by using
Escherichia coli O antisera (Denka Seiken, Tokyo, Japan), and
the flagellar (H) serotype was determined using reference sera
obtained from the Statens Serum Institut (Hillerød, Denmark).
SUSCEPTIBILITY TESTING AND GENETIC ANALYSIS
Norfloxacin (NOR) was purchased from Sigma-Aldrich (St Louis,
MO). Other antibiotics were obtained as described previously
(Sato et al., 2011). Susceptibility to fluoroquinolones [CIP, LVX,
urifloxacin (URX), sitafloxacin (STX), and NOR], nalidixic acid
(NAL), CHL, and TMP was determined by the agar plate
dilution method, according to CLSI guidelines (Clinical and
Laboratory Standards Institute, 2011). Phe-Arg-β-naphthylamide
(PAβN; final concentration, 20mg/L), which is an inhibitor of
the resistance-nodulation-division (RND)-type efflux pump, was
purchased from Sigma-Aldrich.
The presence of oqxA, oqxB, and qnrS was determined
by PCR (Sorensen et al., 2003; Cattoir et al., 2007). Full-
length nucleotide sequences of oqxAB, qnrS, acrA, acrB, acrR,
acrE, acrF, acrS, tolC, soxS, soxR, and rob were determined by
PCR and direct sequencing by using the primer pairs listed
in Table 1. The nucleotide sequence of marR was determined
as previously described (Lindgren et al., 2003). Nucleotide
sequences were determined using a BigDye Terminator v3.1
Cycle Sequencing Kit (Life Technologies, Carlsbad, CA), and
sequencing was performed in a 3130 Genetic Analyzer (Life
Technologies). The oqxAB nucleotide sequence of HUE1 was
submitted to GenBank (accession number AB601773). All gene
sequences, except those of oqxAB and qnrS, were compared with
those of Escherichia coli strain K12 substrain MG1655, which
was deposited in GenBank (accession number U00096), as the
reference strain.
TRANSFORMATION OF PLASMIDS DERIVED FROM HUE1 INTO DH5α
Plasmids were isolated from HUE1 as described previously (Kado
and Liu, 1981). The plasmids were electroporated into E. coli
DH5α (Takara, Shiga, Japan) by using an ECM600 (BTX, San
Diego, CA, USA) under the following conditions: voltage, 1.8 kV;
capacitance, 25μF; and resistance, 200 ohms. oqxAB and/or qnrS
transformants were screened using Muller-Hinton (MH) agar
containing CIP, TMP, and CHL at concentrations ranging from
2- to 8-fold of the respective MIC values.
Table 1 | Sequences of primers used for PCR and DNA sequencing in this study.
Gene Forward primer or fluorescent probe (5′–3′) Reverse primer (5′–3′)
acrA acrA-1F (caccggcagtttgaggatcg) acrA-1R (gcgcggatcaatctggctta)
acrA-2F (gtcgttgctggactgggtca) acrA-2R (atgaacaaaaacagagggtttacg)
acrB acrB-1F (tcaatgatgatcgacagtatggct) acrB-1R (ggaacaactggcgagcaaac)
acrB-2F (agcggaacgaccagcataac) acrB-2R (gcgggacgtggtcagaatac)
acrB-3F (ccagcctggtcaatcagctc) acrB-3R (gcgtgttatggcggaagaag)
acrB-4F (cgaataccgccgacagtacc) acrB-4R (ggatgaacccgaatgagctg)
acrB-5F (caggattttgccgaactcttca) acrB-5R (ataaccagcaagccgcaagc)
acrE acrE-F(atagccgaagttcgcccaca) acrE-R (ctgcgggggtatcggtagtg)
acrF acrF-1F (cagtcaggcgattggcgata) acrF-1R (accaccgagccgtcactgtt)
acrF-2F (cagcgttaccagggcaacaa) acrF-2R (attttgccgacgctgttggt)
acrF-3F (cgctgcttaaacccgtctctg) acrF-3R (cagtcgcggagagccataca)
acrF-4F (cgctgggtgggacttacgtt) acrF-4R (ttatcctttaaagcaacggcgga)
acrR acrR-F (atcagaacgaccgccagagg) acrR-R (ttattcgttagtggcaggattacga)
acrS acrS-F (ttacatgacacttaattcattcgtttga) acrS-R (tgcacatcgctgccttcagt)
oqxAB oqxAB-1F (acatttaccggaataaaaat) oqxAB-1R (ggcgaggttttgatagtgga)
oqxAB-2F (acggtgtacgtctactttga) oqxAB-2R (gtctcggcaatcactttcg)
oqxAB-3F (gcgcgcggagtatcccggcg) oqxAB-3R (ccgcatccttattgttgagc)
oqxAB-4F (atcgagatgggttccggtag) oqxAB-4R (taaacggacggaaaatccag)
oqxAB-5F (tggcggccctgctgttaaag) oqxAB-5R (gataggtctgcagcgtaccg)
oqxAB-6F (ctggacgtgcaggtcgatcg) oqxAB-6R (gataaaggcgatggaggtcat)
oqxAB-7F (gagctgtcgaagcagatcct) oqxAB-7R (tgcgacccggtgccggaaat)
qnrS qnrSseq-F (ttagtcaggataaacaacaataccca) qnrSseq-R (atggaaacctacaatcatacatatcgg)
rob robA-F (catctggacgcccctgcatt) robA-R (agccaatggccccagcatta)
soxSR soxSR-F (gcgctattgccagggatggt) soxSR-R (tgtgttgacgtcgggggaaa)
tolC tolC-1F (cgggcaggttgtctggctta) tolC-1R (ctggctcaagcgtgcctgta)
tolC-2F (gctgcgctgaatgtcgaaaa) tolC-2R (tgcgtggcgtatggattttg)
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy May 2013 | Volume 4 | Article 125 | 2
Sato et al. Fluoroquinolone resistance in non-QRDR-mutated E. coli
PLASMID CURING, PLASMID RE-INTRODUCTION, AND SOUTHERN
HYBRIDIZATION
Curing of plasmids and generation of spontaneous mutants were
performed as previously described, with slight modifications
(Deane and Rawlings, 2004). Briefly, strains were grown in 4mL
LB broth at 40◦C and incubated for periods ranging from a week
to a month. Then, clones were picked and grown in MH agar
containing sub-MIC concentrations of CIP, TMP, and CHL or
no antimicrobials, in order to obtain oqxAB- and/or qnrS-cured
clones. Re-introduction of plasmids harboring oqxAB and/or
qnrS into plasmid-curedmutants was performed using electropo-
ration as described above. The presence of oqxA, oqxB, and qnrS
was detected by PCR and Southern hybridization of plasmids, as
previously described (Tamamura et al., 2011). Probes for oqxB
and qnrS1 were prepared by PCR by using specific primers, as
described previously (Cattoir et al., 2007; Bin Kim et al., 2009).
Probe labeling was carried out using a PCR DIG labeling mix
(Roche Diagnostics, Tokyo, Japan).
REAL-TIME REVERSE-TRANSCRIPTION (RT) PCR
Overnight cultures were diluted 1:100 in LB broth and grown to
the mid-logarithmic phase. RNA was isolated using an RNeasy
Mini kit (Qiagen, Hilden, Germany). Gene expression was esti-
mated by quantitative real-time reverse-transcription (RT)-PCR
by using the probe and primer pairs shown in Table 2. RT-PCR
was performed using a QuantiTect Probe RT-PCR kit (Qiagen)
in 20μL reactions containing 2.5 ng of purified RNA, 0.2μM of
probe, and 0.5μM of each of the forward and reverse primers.
The cycling conditions included reverse transcription at 50◦C for
20min and PCR involving initial activation at 95◦C for 15min
and 45 cycles each consisting of 1min at 55◦C and 30 s at 60◦C,
in a LightCycler 480 system (Roche, Mannheim, Germany). The
E. coli strain AG100 (K-12 argE3 thi-1 rpsL xyl mtl D(gal-uvrB)
supE44) (Okusu et al., 1996), which was gifted by Dr. Helen I.
Zgurskaya (University of Oklahoma, USA), was used as a con-
trol. Expression levels of gapA were used to normalize expression
ratios. Data, except for those of oqxB and qnrS1, were calibrated
against expression levels in AG100, which were set as 1, to deter-
mine fold changes in expression. Data for oqxB and qnrS1 were
calibrated to the respective levels in HUE1, which were set as 1.
The data shown represent the mean values of three independent
experiments.
CONSTRUCTION OF GENE DELETION MUTANTS
Gene disruption was performed by Red/ET recombination by
using the Quick and Easy Gene Deletion kit (Gene Bridges
GmbH, Heidelberg, Germany) according to the manufacturer’s
protocol. The relevant forward and reverse primers are shown
in Table 2. Briefly, target gene-specific minigenes, containing a
neomycin/kanamycin- or hygromycin-resistance cassette, were
constructed by PCR with primers containing 46 bp of upstream
and downstream sequences that contained the start codon or the
stop codon (or the last codon before the stop codon) of the tar-
get genes, respectively (Table 2). The target genes were replaced
with minigenes containing the drug-resistance cassette by using
Red/ET recombination. The integration of interrupted genes was
verified by PCR and DNA sequencing.
PLASMID CONSTRUCTION
Each of the wild-type acrR and wild-type marR DNA segments
were amplified by PCR using DH5α genomic DNA as a tem-
plate and primers containing the A1 T7 promoter, consensus
Shine-Dalgarno, and HindIII restriction sites (Table 2), which
were designed according to a previous report (Edgar et al., 2012).
These PCR products were cloned into the HindIII site of pUC19
(wt-acrR or wt-marR), and the plasmids were then transformed
into HUE1.
ACCUMULATION ASSAYS
Intracellular CIP concentrations were assayed using a fluoromet-
ric uptake assay (Usui et al., 2009). Forty milligrams of wet cells
was treated with CIP (final concentration, 10mg/L) in the pres-
ence or absence of carbonyl cyanide m-chlorophenylhydrazone
(CCCP, Sigma-Aldrich; final concentration, 150μM). The flu-
orescence of CIP was measured at excitation and emission
wavelengths of 277 and 445 nm, respectively, by using an RF-
5000 fluorescence spectrophotometer (Shimadzu, Kyoto, Japan)
(Nakaminami et al., 2010). The data shown represent the mean
value ± standard deviation values calculated from at least three
independent experiments.
STATISTICAL ANALYSIS
Statistical significance was determined by the Student’s t-test.
Differences among more than three groups were determined
using the Mann–Whitney U-test. A P-value of 0.05 or less was
considered statistically significant.
RESULTS
CHARACTERISTICS OF HUE1 AND GENETIC ANALYSIS OF OqxAB AND
QnrS
HUE1 was identified as ST48 (according to the Max-Planck-
Institut für Infektionsbiologie database), phylogenetic group A
(Sato et al., 2011), and O125:H37. Its NOR exceeded the break-
points established by the CLSI, similarly with CIP and LVX
previously tested (Sato et al., 2011). A 4421-bp DNA segment
containing oqxAB and a 647-bp DNA segment containing qnrS
derived from HUE1 were sequenced. The sequence of oqxAB was
100% identical to that of plasmid pOLA52 (accession number
EU370913) in an E. coli isolate obtained from swine in Sweden
(Hansen et al., 2004). The sequence of qnrS was 100% identical
to that of qnrS1 in Shigella flexneri (accession number AB187515)
(Hata et al., 2005). Plasmid profiling and Southern blotting anal-
ysis showed that oqxAB and qnrS1 were located on 2 independent
plasmids, pHFQ1 (>165 kb) and pHFQ2 (>100 kb), respectively
(Figure 1, lane 1).
Introduction of pHFQ1 (carrying oqxAB) into DH5α slightly
increased the MICs for fluoroquinolones (except for LVX) and
NAL, as compared with those for the host strain DH5α (Table 3).
Introduction of pHFQ2 (carrying qnrS1) resulted in higher MICs
for fluoroquinolones andNAL than those seen for DH5α/pHFQ1.
However, introduction of both pHFQ1 and pHFQ2 into DH5α
did not increase the MICs beyond the breakpoints for fluoro-
quinolone. Deletion of oqxAB or qnrS from the transformants
by Red/ET recombination reverted MICs for fluoroquinolones to
levels similar to those of DH5α.
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FIGURE 1 | Plasmid profile and Southern hybridization of oqxB
and qnrS1 in HUE1, its oqxAB- and/or qnrS1-cured strains,
and oqxAB− and/or qnrS1−re-introduced strains. (A) Plasmid
profile. Electrophoresis was performed at 100 V for 70min with a
0.8% agarose gel. (B) Southern hybridization with the oqxB probe.
(C) Southern hybridization with the qnrS probe. Lane 1, HUE1; lane
2, HUE1A2; lane 3, HUE1A; lane 4, HUE1A-Curoqxqnr; lane 5,
HUE1A-Reoqx; lane 6, HUE1A-Reqnr; lane 7, HUE1A-Reoqxqnr; lane
8, HUE1; lane 9, HUE1B-Curoqx; lane 10, HUE1B-Curoqxqnr; lane 11,
HUE1B-Reqnr; lane 12, HUE1B-Reoqx; lane 13, HUE1B-Reoqxqnr; R,
DNA Molecular Weight MarkII, DIG-labeled: r, BAC-Tracker Supercoiled
DNA Ladder.
CHARACTERIZATION OF MUTANTS DERIVED FROM PLASMID CURING
AND PLASMID RE-INTRODUCTION
Eleven mutants obtained by curing and re-introduction of the
plasmids showed altered fluoroquinolone MICs (Figure 1 and
Table 3). These mutants were grouped into two types (groups
A and B). In the case of group A, we first obtained two strains,
named HUE1A and HUE1A2. Although these two mutants
still harbored pHFQ1 (carrying oqxAB) and pHFQ2 (carrying
qnrS1; Figure 1, lanes 2 and 3), the MICs of NAL and fluoro-
quinolones were 2- or 4-fold lower than those of the parental
strain, HUE1. Secondary screening of mutants by using HUE1A
yielded a mutant, HUE1A-Curoqxqnr, which had lost pHFQ1
and pHFQ2 (Figure 1, lane 4). This mutant had 16- to 64-
fold lower MICs for fluoroquinolones than the parental strain,
HUE1A. Re-introduction of pHFQ1 and pHFQ2 into HUE1A-
Curoqxqnr yielded HUE1A-Reoqxqnr, in which fluoroquinolone
MICs recovered to the levels seen for HUE1A, but not to theMICs
of the parent strain, HUE1.
In the case of group B, we first obtained a mutant, HUE1B-
Curoqx, which had lost pHFQ1; a second screening using
HUE1B-Curoqx yielded HUE1B-Curoqxqnr, which had lost both
pHFQ1 and pHFQ2 (Figure 1, lanes 9 and 10). Interestingly,
the fluoroquinolone MICs of HUE1B-Curoqxqnr were 512- and
1280-fold lower than those of HUE1 and were 4- to 16-fold lower
than those of HUE1A-Curoqxqnr (Table 3).
Similar differences with respect to the MICs of groups A and
B were also observed for the mutant series in which pHFQ2
(carrying qnrS1) had been re-introduced. However, most fluoro-
quinolone MICs of group B strains in which pHFQ1 (carrying
oqxAB) had been re-introduced were only 2- to 4-fold lower than
those of mutants in group A.
EFFECTS OF EFFLUX PUMP INHIBITORS AND GENETIC ANALYSIS OF
EFFLUX PUMP COMPONENTS IN THE HUE1 STRAIN AND ITS MUTANTS
The efflux pump inhibitor PAβN reduced the fluoroquinolone
MICs of the HUE1 strain from 4- to 16-fold (Table 3). In mutants
derived from plasmid curing in groups A and B, the effects of
PAβN were less than in the parental strain, HUE1. Remarkably,
the fluoroquinolone MICs of three mutants that lost oqxAB
in group B (HUE1B-Curoqxqnr, HUE1B-Curoqx, and HUE1B-
Reqnr) were barely affected by PAβN.
HUE1 exhibited higher mRNA expression of efflux pump
genes (acrA, acrB, acrE, acrD, mdtK, mdfA, and tolC) and
their global activators (soxS, marA, and rob) than the control
strains, AG100 and DH5α. In contrast, ompF expression was
lower in HUE1 than in the control strains (Table 4). Moreover,
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Table 3 | Fluoroquinolones and NAL susceptibilities of HUE1, transformants derived from DH5α, and HUE1mutants derived from plasmid
curing and reintroduction.
Strain PCR MIC (mg/L)
oqxAB qnrS1 CIP LVX URX STX NOR NAL
HUE1 + + 4 (×4)a 8 (×16) 4 (×4) 2 (×16) 16 128
TRANSFORMATION OF pHFQ1 AND pHFQ2
DH5α − − 0.015 0.03 0.015 0.004 0.03 32
DH5α/pHFQ1 + − 0.03 0.03 0.03 0.015 0.06 64
DH5α/pHFQ1(oqxAB::hygr) − − 0.015 0.03 0.015 0.004 0.03 32
DH5α/pHFQ2 − + 0.125 0.5 0.125 0.125 0.25 128
DH5α/pHFQ2(qnrS1::hygr) − − 0.015 0.03 0.015 0.004 0.03 32
DH5α/pHFQ1-pHFQ2 + + 0.25 0.5 0.125 0.25 0.25 >128
MUTANTS OBTAINED FROM PLASMID CURING
<Group A>
HUE1A and HUE1A2 + + 2 (×2) 2 (×4) 2 (×2) 1 (×8) 8 64
HUE1A-Curoqxqnr − − 0.06 (×2) 0.125 (×4) 0.03 (×1) 0.03 (×4) 0.5 16
HUE1A-Reoqx + − 0.125 (×4) 0.125 (×4) 0.125 (×2) 0.06 (×8) 0.5 32
HUE1A-Reqnr − + 1 (×2) 1 (×4) 1 (×1) 0.5 (×4) 8 64
HUE1A-Reoqxqnr + + 2 (×2) 2 (×4) 2 (×2) 1 (×8) 8 64
<Group B>
HUE1B-Curoqx − + 0.25 (×1) 0.125 (×1) 0.125 (×1) 0.03 (×1) 0.25 4
HUE1B-Curoqxqnr − − 0.008 (×1) 0.008 (×1) 0.008 (×1) 0.004 (×1) 0.03 1
HUE1B-Reoqx + − 0.125 (×8) 0.06 (×8) 0.03 (×2) 0.03 (×8) 0.25 16
HUE1B-Reqnr − + 0.125 (×1) 0.125 (×1) 0.125 (×1) 0.03 (×1) 0.25 4
HUE1B-Reoqxqnr + + 1 (×4) 1 (×4) 0.5 (×2) 0.25 (×8) 4 32
aReduction of MIC by PAβN (-fold), rresistance.
Table 4 | mRNA expression levels of global activators, efflux pumps, and ompF genes in HUE1, HUE1A, HUE1A-Curoqxqnr, and
HUE1B-Curoqqnr.
Strain Expression level (relative amount of AG100; in terms of fold change)
Global activators Efflux pumps Porin
soxS marA rob acrA acrB acrE acrD mdtK mdfA tolC ompF
HUE1 9.80 147.77 8.17 4.67 6.81 8.70 8.34 6.43 6.76 2.83 0.19
HUE1A 4.82 80.65 4.56 2.89 3.55 4.42 3.93 3.21 3.70 2.10 0.15
HUE1A-Curoqxqnr 4.99 82.95 4.81 3.04 3.61 4.33 4.06 2.99 3.77 2.21 0.15
HUE1B-Curoqxqnr 10.02 154.69 8.55 4.21 5.42 10.52 10.20 7.66 7.85 3.20 0.24
DH5α 1.83 21.84 1.44 1.28 1.29 0.69 0.59 0.76 1.17 1.62 2.78
in HUE1A and HUE1A-Curoqxqnr, the mRNA expression of
efflux pumps and their regulatory genes were approximately
half of those in HUE1, while those of HUE1B-Curoqxqnr were
similar to those in HUE1. The mRNA expression of qnrS1
and oqxB was not significantly different among the HUE1,
HUE1A, HUE1A-Reoqxqnr, and HUE1B-Reoqxqnr strains (data
not shown).
Next, we determined the full DNA sequences of efflux pump
genes (acrA, acrB, acrE, acrF, and tolC) and their regulatory genes
(marR, acrS, soxS, soxR, rob, and acrR). Although most genes in
HUE1 and its plasmid-cured mutants were wild-type mutants,
we found some mutations. acrR was disrupted by the insertion
of a transposon, an IS3–IS629 element, in HUE1 and group
A HUE1A-Curoqxqnr (Figure 2). HUE1B-Curoqxqnr (group B)
had a deletion across acrR (corresponding to amino acids from
Met-1 to Leu-73 of AcrR) and acrA (corresponding to amino
acids from Met-1 to Asp-106 of AcrA), in addition to the inser-
tion of the IS3–IS629 element. In addition, a nucleotide deletion
of cytosine at position 223 ofmarR caused a frameshift in HUE1,
HUE1A-Curoqxqnr, and HUE1B-Curoqxqnr.
www.frontiersin.org May 2013 | Volume 4 | Article 125 | 7
Sato et al. Fluoroquinolone resistance in non-QRDR-mutated E. coli
FIGURE 2 | Schematic representation of the acrAB−acrR region in
HUE1, group A mutants, and group B mutants. (A) Escherichia coli K12
MG1655 (accession no U00096). (B) HUE1 and HUE1A-Curoqxqnr (group A).
(C) HUE1B-Curoqxqnr (group B). aa., Amino acids. ∗Position of primer pairs
(acrART-F and acrART-R) used in RT-PCR (corresponding to amino acids
272–294 in AcrA).
CHARACTERIZATION OF KNOCKOUT MUTANTS PREPARED BY RED/ET
RECOMBINATION
We obtained a series of gene knockout mutants by Red/RT
recombination. The fluoroquinolone MICs of HUE1-oqxAB,
HUE1-qnrS1, and HUE1-oqxAB qnrS1 were reduced by 2- or
4-fold, 16- or 32-fold, and 32- or 64-fold, as compared to those
of HUE1, respectively (Table 5). HUE1-acrA, HUE1-acrB,
and HUE1-acrAB demonstrated 4- or 8-fold lower MICs than
HUE1. HUE1-acrA oqxAB exhibited 32- or 64-fold lower fluo-
roquinoloneMICs and HUE1-acrA qnrS1 exhibited 64- or 128-
fold lower fluoroquinolone MICs than HUE1. HUE1-oqxAB
did not exhibit marked changes in fluoroquinolone MICs com-
pared with those of HUE1, while HUE1-acrAB oqxAB demon-
strated larger fold changes, ranging from 4- to 16-fold lower, than
HUE1-acrAB.
Knockout of tolC markedly decreased fluoroquinolone MICs
by 64- or 128-fold, and the MICs of the tolC knockout mutant
(HUE1-tolC) were not altered by additional knockout of acrAB
or oqxAB (HUE1-tolC acrAB or HUE1-tolC oqxAB). HUE1-
tolC qnrS1 showed the lowest fluoroquinolone MICs, ranging
from 512- to 2056-fold lower than those of HUE1. Mutants in
which other efflux pump-associated genes, acrF, acrD, mdtK,
and mdfA, were knocked out showed 2- to 4-fold lower flu-
oroquinolone MICs than did HUE1 (Table 5). The mutant
derived from HUE1B-Curoqxqnr with knockout acrB (HUE1B-
Curoqxqnr-acrB) did not show altered fluoroquinolone MICs,
when compared to HUE1B-Curoqxqnr.
Transformation of HUE1 with plasmids encoding wild-type
acrR or wild-type marR (HUE1-wt-acrR and HUE1-wt-marR)
resulted in fluoroquinolone MICs that were 2- or 4-fold lower
than those for HUE1 (data not shown). HUE1-wt-acrR and
HUE1-wt-marR resulted in reduced mRNA expression levels of
acrA and acrB, and HUE1-wt-marR also exhibited a significant
reduction in the expression of marA compared with that for
HUE1 (Figure 3).
INTRACELLULAR FLUOROQUINOLONE CONCENTRATIONS
The intracellular CIP concentration in HUE1 was approxi-
mately 2.3-fold lower than that in DH5α (p < 0.05; Figure 4).
Intracellular CIP concentrations in HUE1A and HUE1A-
Curoqxqnr were minimally, albeit significantly, higher than those
of the parental strain, HUE1 (p < 0.05). In contrast, the intra-
cellular CIP concentration in HUE1B-Curoqxqnr was markedly
higher than those in HUE1, HUE1A, and HUE1A-Curoqxqnr
(p < 0.05), and was similar to those of HUE1-acrA oqxAB,
and HUE1-acrAB oqxAB (Figure 4). HUE1-acrA and HUE1-
acrAB exhibited significantly increased intracellular CIP con-
centrations compared with that for HUE1 (p < 0.05). However,
the intracellular CIP concentrations of acrD-, acrF-, mdtK-, and
mdfA-knockout HUE1 mutants were slightly higher, but not
significantly different from that for HUE1 (p > 0.05; data not
shown). The intracellular CIP concentration in HUE1-oqxAB
was also not significantly different from that of HUE1; how-
ever, HUE1-acrA oqxAB and HUE1-acrAB oqxAB exhibited
a clear increase in intracellular CIP levels compared to that
in HUE1-acrA or HUE1-acrAB (p < 0.05). HUE1-tolC
showed the highest intracellular CIP concentrations (Figure 4),
which were not altered by additional knockout of acrAB or oqxAB
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Table 5 | Fluoroquinolones susceptibilities of Red/ET recombination mutants derived from HUE1.
Strain MIC (mg/L) MIC reduction (-fold)a
CIP LVX URX STX NOR
HUE1 4 8 4 2 16 –
HUE1- oqxAB 2 2 1 0.5 8 2 or 4
HUE1-qnrS1 0.25 0.25 0.125 0.125 0.5 16 or 32
HUE1-oqxAB qnrS1 0.06 0.125 0.06 0.06 0.5 32 or 64
HUE1-acrA 1 1 0.5 0.25 4 4 or 8
HUE1-acrA oqxAB 0.125 0.125 0.125 0.03 0.25 32 or 64
HUE1-acrA qnrS1 0.06 0.06 0.03 0.03 0.25 64 or 128
HUE1-acrB 1 1 0.5 0.25 4 4 or 8
HUE1-acrAB 1 1 0.5 0.25 4 4 or 8
HUE1-acrAB oqxAB 0.125 0.125 0.125 0.03 0.25 32 or 64
HUE1-acrAB qnrS1 0.06 0.06 0.03 0.03 0.5 32–128,
HUE1-tolC 0.06 0.125 0.06 0.015 0.25 64 or 128
HUE1-tolC acrAB 0.06 0.125 0.125 0.03 0.25 32 or 64
HUE1-tolC oqxAB 0.06 0.125 0.125 0.03 0.25 32 or 64
HUE1-tolC qnrS1 0.002 0.004 0.008 0.002 0.015 512–2056
HUE1B-Curoqxqnr 0.008 0.008 0.008 0.004 0.03 512 or 1024
HUE1B-Curoqxqnr-acrB 0.008 0.008 0.008 0.004 0.03 512 or 1024
HUE1-acrF 2 2 2 1 8 2 or 4
HUE1-acrD 2 4 2 1 8 2
HUE1-mdtK 2 4 1 1 8 2 or 4
HUE1-mdfA 2 4 2 1 8 2 or 4
aRelative value of HUE1.
(HUE1-tolC acrAB or HUE1-tolC oqxAB; data not shown).
Addition of CCCP resulted in increased intracellular CIP con-
centrations in all strains, with levels ranging from 21.8 ± 2.3 to
25.8 ± 5.2 ng/mg wet cells; there were no statistical differences
(p > 0.05, data not shown).
DISCUSSION
It is known that QRDR mutations are required for the flu-
oroquinolone MICs to exceed the breakpoints (Jacoby, 2005;
Hansen et al., 2007; Cesaro et al., 2008; Zhao et al., 2010).
To our knowledge, a fluoroquinolone-resistant strain without
QRDR mutations has been reported only in a laboratory-derived
resistant mutant strain of Acinetobacter baumannii that had been
selected by in vitro fluoroquinolone exposure experiments; how-
ever, the resistance mechanism of this strain remains unclear
(Chopra and Galande, 2011). In the current study, we demon-
strated the fluoroquinolone-resistance mechanisms in an E. coli
clinical isolate, HUE1, which lacks mutations in QRDRs (Sato
et al., 2011).
HUE1 possessed two PMQRs on different plasmids,
pHFQ1 (harboring oqxAB) and pHFQ2 (harboring qnrS1).
Transformation experiments using DH5α as a host clearly
showed that oqxAB and qnrS1 did in fact contribute to fluoro-
quinolone resistance. However, transformants containing both
plasmids still did not exceed the MIC breakpoints.
It has been suggested that some efflux pumps are associ-
ated with fluoroquinolone resistance in HUE1. AcrAB-TolC is
known to be the most important chromosomally encoded efflux
pump related to fluoroquinolone resistance in Escherichia coli
(Poole, 2005). During plasmid curing, a series of HUE1 group
B mutants showed markedly lower fluoroquinolone MICs and
higher intracellular CIP concentrations than did HUE1 and its
group A mutants, whereas these mutants had mRNA expression
levels of efflux pumps similar to those of HUE1. We found that
group B mutants possessed deletions across parts of acrA. AcrA
is an outer membrane protein that binds to AcrB (which plays
a role in fluoroquinolone excretion) and TolC (an outer mem-
brane factor) (Kobayashi et al., 2001; Elkins and Nikaido, 2003;
Ge et al., 2009). The deleted region of AcrA in group B mutants
involves an α-β barrel (53–61 amino acid residues), which forms
the AcrB-binding domain, and a part of an α-helical hairpin (99–
172 amino acid residues), which forms the TolC-binding domain
(Ge et al., 2009). Fluoroquinolone MICs of the acrA-knockout
HUE1 mutant (HUE1-acrA) were similar to those of HUE1B-
Reoqxqnr (a group B mutant that possesses oqxAB and qnrS1),
HUE1-acrB, and HUE1-acrAB. Moreover, the intracellular
CIP concentration in HUE1B-Curoqxqnr (a group B mutant
that had been cured of oqxAB and qnrS1) was not different
from that in HUE1B-Curoqxqnr-acrB. These results suggested
that reduction of fluoroquinolone MICs in group B strains was
caused by functional disruption of AcrAB–TolC, which did not
allow cooperation between AcrA and AcrB and TolC, indicat-
ing that fluoroquinolone resistance in HUE1 is partially due to
AcrAB–TolC.
www.frontiersin.org May 2013 | Volume 4 | Article 125 | 9
Sato et al. Fluoroquinolone resistance in non-QRDR-mutated E. coli
FIGURE 3 | mRNA expression levels ofmarA, acrA, and acrB in HUE1
and its acrR ormarR transformants. The values indicate the expression
levels of indicated genes relative to those in HUE1 (fold-changes). White,
HUE1; gray, HUE1-pUC19; diagonal line, HUE1-wt-acrR (HUE1 strain
transformed wild-type of acrR); black, HUE1-wt-marR (HUE1 strain
transformed wild-type marR). ∗p < 0.05 compared to HUE1. Data represent
the mean ± standard deviation values calculated from at least three
independent experiments.
FIGURE 4 | Intracellular concentrations of CIP in HUE1 and its mutants
obtained from plasmid curing and Red/ET recombination. Data represent
the mean ± standard deviation values of the results from three independent
experiments. ∗p < 0.05 compared to HUE1. †p < 0.05 between HUE1-acrA
and HUE1-acrA oqxAB and between HUE1-acrAB and HUE1-acrAB
oqxAB, respectively.
AcrAB-TolC expression is controlled by several activators (i.e.,
soxS, marA, and rob) and repressors (i.e., acrR, marR, and soxR)
(White et al., 1997; Poole, 2005; Keeney et al., 2008). HUE1 exhib-
ited higher expression of acrA, acrB, tolC and these activators.
In addition, HUE1 had concomitant disruption of the acrR and
marR repressors. AcrR is a local repressor of AcrAB (Wang et al.,
2001), and MarR is a repressor of MarA, which is one of the
global activators of AcrAB (Keeney et al., 2008). Introduction
of wild-type acrR or wild-type marR to HUE1 actually reduced
acrA and acrB mRNA expression and reduced fluoroquinolone
MICs. These data suggested that overexpression of AcrAB–TolC
in HUE1 was mediated by the concomitant disruptions of AcrR
and MarR. However, other mechanisms are also responsible for
the overexpression of AcrAB–TolC and other chromosomally
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encoded efflux pumps, since the group A series of HUE1mutants
was found to have only approximately half of the mRNA expres-
sion levels of chromosomal efflux pump genes, including those
encoding AcrAB, despite having the same disruptions in acrR and
marR as HUE1. This will require further investigation.
Other chromosomally encoded efflux pumps, such as AcrEF–
TolC and AcrD, belonging to the RND family, MdtK (also known
as YdhE or NorE), belonging to the multidrug and toxic com-
pound extrusion family, and MdfA, belonging to the major
facilitator superfamily, also excrete fluoroquinolones (Nishino
and Yamaguchi, 2001; Poole, 2005; Nishino et al., 2006). The
mRNA expression of the related genes were also higher in HUE1,
and HUE1 knockout mutants of these genes exhibited reduced
fluoroquinolone MICs compared to HUE1, although the influ-
ence of these knockouts was weaker than that of AcrAB. These
results indicated that the fluoroquinolone-resistance mechanism
in HUE1 was most likely associated with the overexpression of
AcrAB–TolC, with minor contributions of other chromosomally
encoded efflux pumps, in addition to 2 PMQRs, viz., oqxAB and
qnrS1.
OqxAB belongs to the RND-type efflux pump family, as does
AcrAB (Hansen et al., 2004). Although OqxAB did not cause
marked changes in fluoroquinolone MICs and intracellular CIP
concentrations, we observed more distinct changes following
acrAB deletion. OqxAB requires TolC to excrete AMP, CHL, and
OLA, as does AcrAB (Hansen et al., 2004). In this study, knockout
of tolCmarkedly decreased fluoroquinoloneMICs and intracellu-
lar CIP concentrations and negated the effects of both acrAB and
oqxAB. This finding indicated that OqxAB, in conjunction with
TolC, was also involved in mediating decreased fluoroquinolone
susceptibility. TolC is therefore implicated in the functions of both
AcrAB and OqxAB. Although OqxAB minimally contributed to
fluoroquinolone resistance in HUE1, it may largely contribute to
supplementation of AcrAB functions. TolC is also required for
the function of several efflux pumps (other than AcrAB), such as
AcrEF and AcrD, in S. enterica serovar Typhimurium (Horiyama
et al., 2010). Therefore, overexpression of TolC should also be an
important element in the fluoroquinolone-resistance mechanism
in HUE1 cells, as verified by our finding of the greatest reduction
in fluoroquinolone MICs by knockout of tolC.
In conclusion, this study is the first to reveal the existence of
a fluoroquinolone-resistance mechanism that is mediated with-
out QRDR mutations in the E. coli clinical isolate, HUE1. This
mechanism involved the concomitant presence of oqxAB and
qnrS1 and was associated with the overexpression of AcrAB, other
chromosomally encoded efflux pumps, and TolC. HUE1 was
identified as phylogenic group A−O125:H37−ST48. This clonal
group has also been isolated from humans and animals world-
wide (Jorgensen et al., 2010; Bortolaia et al., 2011; Croxall et al.,
2011). However, the susceptibilities of ST48 strains to fluoro-
quinolone compounds vary and have not yet been defined in all
cases. Therefore, further epidemiological and molecular biology
analyses of the ST48 lineage are required.
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